Dr. Siddhartha Ganguly ...

Dr. Siddhartha Ganguly

Claim this profile

Houston Methodist Hospital

Studies Multiple Myeloma
Studies Mantle Cell Lymphoma
6 reported clinical trials
10 drugs studied

Area of expertise

1

Multiple Myeloma

Siddhartha Ganguly has run 5 trials for Multiple Myeloma. Some of their research focus areas include:

Stage III
Stage IV
2

Mantle Cell Lymphoma

Siddhartha Ganguly has run 1 trial for Mantle Cell Lymphoma. Some of their research focus areas include:

CCND1 positive
t(11;14) positive

Affiliated Hospitals

Image of trial facility.

Houston Methodist Hospital

Image of trial facility.

Houston Methodist San Jacinto Hospital

Clinical Trials Siddhartha Ganguly is currently running

Image of trial facility.

Iberdomide

for Multiple Myeloma

This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell \[CAR-T\] therapy) for multiple myeloma. The usual approach after treatment with idecabtagene vicleucel is to monitor the multiple myeloma without giving myeloma medications. There is currently no medication approved specifically for use after idecabtagene vicleucel treatment. Upon administration, iberdomide modifies the immune system and activates immune cells called T-cells, which could enhance the effectiveness of idecabtagene vicleucel. Iberdomide may keep multiple myeloma under control for longer than the usual approach (disease monitoring) after idecabtagene vicleucel, and may help multiple myeloma patients live longer.

Recruiting

1 award

Phase 2

10 criteria

Image of trial facility.

Lenalidomide + Dexamethasone +/- Daratumumab

for Multiple Myeloma

This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma.

Recruiting

2 awards

Phase 3

12 criteria

More about Siddhartha Ganguly

Clinical Trial Related

8 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Siddhartha Ganguly has experience with

  • Lenalidomide
  • Idecabtagene Vicleucel
  • Fludarabine
  • Cyclophosphamide
  • Autologous Hematopoietic Stem Cell Transplantation
  • Rituximab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Siddhartha Ganguly specialize in?

Is Siddhartha Ganguly currently recruiting for clinical trials?

Are there any treatments that Siddhartha Ganguly has studied deeply?

What is the best way to schedule an appointment with Siddhartha Ganguly?

What is the office address of Siddhartha Ganguly?

Is there any support for travel costs?

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Terms of Service·Privacy Policy·Cookies·Security